B. Larder

B. Larder, B A Larder, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

K. Hertogs, B. Larder, S. Bloor, 2000, AIDS.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215

D. I. Stuart, D. Stuart, D. Stammers, 2002, Journal of Virology.

Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

T. Kunkel, B. Larder, S. Kemp, 1992, The Journal of biological chemistry.

A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine

John W. Mellors, Brendan A. Larder, Stuart Bloor, 1998, Journal of Virology.

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.

D. Stammers, B. Larder, A. Aitken, 1988, Biochemistry.

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

K. Hertogs, W. Verbiest, B. Larder, 2001 .

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

S D Kemp, B. Larder, S. Kemp, 1991, AIDS.

Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir

B. Larder, G. Darby, 1986, Antimicrobial Agents and Chemotherapy.

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

B. Larder, 1992, Antimicrobial Agents and Chemotherapy.

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates

B. Larder, P. Kellam, P Kellam, 1994, Antimicrobial Agents and Chemotherapy.

Mutations in RT and Protease III -93 NOV 95 Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance

B. Larder, J. Mellors, R. Schinazi, 1996 .

11 Inhibitors of HIV Reverse Transcriptase as Antiviral Agents and Drug Resistance

B. Larder, 1993 .

Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity.

B. Larder, K. Moelling, T. Schulze, 1991, The Journal of general virology.

Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.

P. Harrigan, B. Larder, S. Bruisten, 1997, AIDS research and human retroviruses.

Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative – Uganda

K. Hertogs, B. Larder, P. Weidle, 2003, AIDS (London).

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

Brendan Larder, Lee Bacheler, Kurt Hertogs, 2001, Journal of Virology.

Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing

B. Larder, S. Kemp, P. Kellam, 1993, Nature.

Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma.

K. Hertogs, B. Larder, S. Bloor, 2001, The Journal of infectious diseases.

Key Reports from the XV International HIV Drug Resistance Workshop 2006

D. Richman, B. Larder, J. Mellors, 2007, Antiviral therapy.

virus type 1 isolates. susceptibility of human immunodeficiency phenotypic assay for assessment of drug Recombinant virus assay: a rapid,

B. Larder, P. Kellam, 2014 .

HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort

K. Hertogs, B. Larder, S. Bloor, 2000, Antiviral therapy.

Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture

S D Kemp, B. Larder, S. Kemp, 1991, Journal of virology.

The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors

P. Harrigan, K. Hertogs, R. Pauwels, 1998, AIDS.

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

B. Larder, C. Boucher, P. Kellam, 1992, The Journal of infectious diseases.

Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up

K. Hertogs, B. Larder, B. Clotet, 2001, Antiviral therapy.

Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

P. Harrigan, B. Larder, S. Bloor, 1998, Journal of Virology.

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

P. Harrigan, B. Larder, S. Kemp, 1996, Journal of virology.

Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.

P. Klenerman, B. Larder, A. Edwards, 1994, The Journal of infectious diseases.

A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V

K. Hertogs, B. Larder, S. Bloor, 2000, Antimicrobial Agents and Chemotherapy.

Resistance to antiretroviral therapy among patients in Uganda.

K. Hertogs, B. Larder, S. Bloor, 2001 .

Non‐parametric methods to predict HIV drug susceptibility phenotype from genotype

Brendan Larder, Victor DeGruttola, Kurt Hertogs, 2003, Statistics in medicine.

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.

K. Hertogs, B. Larder, M. Wallace, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro.

B. Larder, J. Lennerstrand, V. Prasad, 2006, The Journal of general virology.

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

J. Tolson, K. Hertogs, B. Larder, 2001, AIDS research and human retroviruses.

Mechanisms of HIV-1 drug resistance.

B. Larder, 2001, AIDS.

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

J W Mulder, R. Schooley, P. Harrigan, 1996, The Journal of infectious diseases.

Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Brendan Larder, Kaneo Yamada, Tsuyoshi Oishi, 2002, Antimicrobial Agents and Chemotherapy.

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

Brendan A. Larder, Stuart Bloor, Margriet Van Houtte, 2000, AIDS.

High Prevalence of Genotypic and Phenotypic HIV‐1 Drug‐Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'lvoire

K. Hertogs, W. Verbiest, B. Larder, 2001, Journal of Acquired Immune Deficiency Syndromes.

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.

D. Stuart, R. Esnouf, A. Hopkins, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates

B. Larder, C. Boucher, P. Kellam, 1993, Antimicrobial Agents and Chemotherapy.

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel

J. Mascola, K. Hertogs, B. Larder, 2000, AIDS.

Genotypic and Phenotypic Evidence of Different Drug-Resistance Mutation Patterns between B and Non-B Subtype Isolates of Human Immunodeficiency Virus Type 1 found in Brazilian Patients Failing HAART

K. Hertogs, B. Larder, A. Tanuri, 2004, Virus Genes.

Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.

K. Hertogs, B. Larder, A. Tanuri, 2000, Virology.

Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates

Brendan A. Larder, P. Harrigan, B. Larder, 2002, Antimicrobial Agents and Chemotherapy.

Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.

A. Wensing, B. Larder, R. Wood, 2013, The Journal of antimicrobial chemotherapy.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response

B. Larder, J. Montaner, B. Clotet, 2019, Journal of acquired immune deficiency syndromes.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Mutational analysis of two conserved sequence motifs in HIV‐1 reverse transcriptase

B. Larder, S. Kemp, D. M. Lowe, 1991, FEBS letters.

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

B. Larder, D. Haas, C. Fletcher, 2000, AIDS research and human retroviruses.

HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies

D. Richman, B. Larder, J. Mellors, 2011, Antiviral therapy.

Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.

K. Hertogs, B. Larder, M. Dybul, 2000, The Journal of infectious diseases.

Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991.

K. Hertogs, B. Larder, P. Easterbrook, 2002, The Journal of infection.

Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study.

K. Hertogs, W. Verbiest, B. Larder, 2001, AIDS.

Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy

K. Hertogs, B. Larder, D. Kempf, 1999 .

Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

B. Larder, S. Bloor, M. Zazzi, 2002, The Journal of infectious diseases.

Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations

D. Richman, B. Larder, J. Mellors, 2008, Antiviral therapy.

Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa

B. Larder, P. Reiss, S. Emery, 2016, Southern African journal of HIV medicine.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

A. Wensing, B. Larder, J. Montaner, 2014, The Journal of antimicrobial chemotherapy.

A Comparison of Three Computational Modelling Methods for the Prediction of Virological Response to Combination Hiv Therapy Author's Personal Copy

Brendan Larder, Dechao Wang, Lidia Ruiz, 2022 .

Cytotoxic T Lymphocyte Lysis Inhibited by Viable HIV Mutants

P. Klenerman, B. Larder, R. Phillips, 1995, Science.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

B. Larder, S. Bloor, J. Weber, 1999, AIDS research and human retroviruses.

Structural Studies on Human Immunodeficiency Virus Reverse Transcriptase

D. Stuart, D. Phillips, D. Stammers, 1990 .

Prevalence of genotypic and phenotypic HIV‐1 drug‐resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS–Drug Access Initiative in Abidjan, Côte d'Ivoire

K. Hertogs, B. Larder, M. Peeters, 2003, AIDS.

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.

Peter Reiss, Hugo Tempelman, Andrew D Revell, 2016, The Journal of antimicrobial chemotherapy.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy

A. d’Arminio Monforte, B. Larder, J. Montaner, 2009, Artif. Intell. Medicine.

The use of computational models to predict response to HIV therapy for clinical cases in Romania.

B. Larder, J. Montaner, M. Youle, 2012, Germs.

Resistance to Antiretroviral Therapy Among Patients in Uganda

K. Hertogs, B. Larder, S. Bloor, 2001, Journal of acquired immune deficiency syndromes.

High Prevalence of Genotypic and Phenotypic HIV‐1 Drug‐Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'lvoire

K. Hertogs, W. Verbiest, B. Larder, 2001 .